On the upside
A Seeking Alpha contributor wrote that Antares Pharma (Nasdaq: ATRS) was a long term investment.
A Seeking Alpha contributor has optimistic expectations for Xoma (Nasdaq: XOMA).
On the downside
Oppenheimer lowered its price target on EMC (NYSE: EMC) yesterday to $32 from $34.
BMO Capital Markets analyst Tim Long lowered his second quarter revenue guidance and full year earnings and revenue outlook for Riverbed Technology (Nasdaq: RVBD).
Navistar International (NYSE: NAV) will introduce its clean engine solution In-Cylinder Technology Plus but investors were concerned about the costs of the new engine.
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 2 on the NYSE and by more than 5 to 2 on Nasdaq. The Russell 2000 which tracks small cap stocks tumbled 10 points to 806.